5 Year Health Care Burden after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Impact of Graft Source

CONCLUSION: Adult recipients of UCBT appear to experience a lower long-term healthcare burden compared to other graft sources. After the first year post-HSCT, recipients of UCBT have fewer clinic visits, laboratory tests, procedures, and medications. This study is the first step in analysis of complex, long-term healthcare burden data in allogeneic HSCT recipients within a single healthcare system. Despite the absence of cost data and details of care outside of Fairview, these data support the hypothesis that healthcare burden varies by graft source with favorable outcomes in long-term survivors after UCBT compared recipients of BM and PBSC.Figure 1.DisclosuresBrunstein: Gamidacell: Research Funding. MacMillan: Angiocrine: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Consultancy; Equillium: Consultancy. Wagner: Novartis: Research Funding; Magenta Therapeutics: Consultancy, Research Funding. Weisdorf: SL Behring: Consultancy; Seattle Genetics: Consultancy; Pharmacyclics: Consultancy; FATE: Consultancy; Equillium: Consultancy. Holtan: Incyte: Consultancy.

Source: Blood - November 21, 2018 Category: Hematology Authors: Garcia Garcia, J., Grillo, S., Cao, Q., Brunstein, C. G., Arora, M., MacMillan, M. L., Wagner, J. E., Weisdorf, D. J., Holtan, S. G. Tags: 904. Outcomes Research-Malignant Conditions: Outcomes in Myeloid Malignancies and Allogeneic Stem Cell Transplant Source Type: research